Anti-CD20 therapy depletes activated myelin-specific CD8+T cells in multiple sclerosis

Joseph J. Sabatino, Michael R. Wilson, Peter A. Calabresi, Stephen L. Hauser, Jonathan P. Schneck, Scott S. ZamvilProceedings of the National Academy of Sciences 2019 · DOI

TL;DR

This study reveals that while the number of myelin-specific CD8+ T cells is similar in multiple sclerosis (MS) patients and healthy individuals, these cells in MS patients show signs of prior activation (memory phenotype and CD20 expression). Importantly, anti-CD20 therapy, commonly used for MS, selectively reduces these activated myelin-specific CD8+ T cells, suggesting they are a key therapeutic target.

What Problem Does This Paper Address?

Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous system (CNS) where the immune system attacks the myelin sheath that insulates nerve fibers. While B cells and CD4+ T cells have long been implicated, the role of CD8+ T cells in MS pathogenesis has been less clear. CD8+ T cells are known for their cytotoxic functions and are found in MS lesions, suggesting they might contribute to myelin damage. However, previous studies struggled to accurately measure myelin-specific CD8+ T cells in their natural state (ex vivo) due to limitations in detection methods. This paper aims to overcome these limitations to precisely characterize myelin-specific CD8+ T cells in untreated MS patients and assess how they respond to anti-CD20 therapy.

Methods

The researchers employed a sophisticated approach using Peptide:MHC I (pMHC I) tetramers. These tetramers are molecular tools that bind specifically to CD8+ T cells that recognize a particular peptide presented by an MHC class I molecule.

Here's a breakdown of their key methods:

  • Epitope Identification and Validation: They first identified potential myelin CD8+ T cell epitopes (specific protein fragments) restricted by common HLA alleles (HLA-A2 and HLA-A3) using in silico prediction and then validated these by measuring their binding to tetramers and their ability to induce cytokine production in T cells. This process identified 5 myelin CD8+ T cell epitopes, including two novel ones.
  • Ex Vivo Tetramer Staining and Enrichment: To accurately measure the frequency of these myelin-specific CD8+ T cells in the blood, they used a combinatorial tetramer staining strategy. This involves using tetramers labeled with different fluorescent colors in unique combinations, allowing for the simultaneous detection of multiple antigen-specific T cells. They also employed a magnetic bead enrichment strategy using anti-PE microbeads to increase the sensitivity of detection for these rare cells.
  • Phenotypic Analysis: Once identified, the T cells were analyzed for their memory status (using markers like CCR7 and CD45RA) and for the expression of CD20, a molecule typically found on B cells but also on activated T cells.
  • Longitudinal Assessment: A subset of MS patients treated with anti-CD20 monoclonal antibody (mAb) therapy (rituximab or ocrelizumab) were studied before and after treatment to assess the impact of the therapy on these specific T cell populations.

Datasets

The study utilized peripheral blood samples from two cohorts:

  • Untreated Relapsing-Remitting Multiple Sclerosis (RR-MS) patients: Used for initial epitope screening and subsequent ex vivo frequency and phenotypic analysis.
  • HLA allele-matched healthy controls: Used for comparison to determine if myelin-specific CD8+ T cell characteristics differ between MS patients and healthy individuals.

A subset of the RR-MS patients (n=9) were also studied longitudinally after receiving anti-CD20 mAb treatment.

Key Insights and Ideas

  • Activated, Not Just More: The core finding is that MS patients don't necessarily have more myelin-specific CD8+ T cells, but rather that these cells are more activated. This is a crucial distinction, shifting the focus from quantity to quality/state of the T cells.
  • CD20 as a T Cell Marker: The study reinforces that CD20 isn't exclusively a B cell marker. Its presence on myelin-specific CD8+ T cells in MS patients suggests a specific, activated phenotype that can be targeted.
  • Anti-CD20's Dual Role: The effectiveness of anti-CD20 therapy in MS is primarily attributed to its action on B cells. This paper provides compelling evidence that it also targets and depletes activated myelin-specific CD8+ T cells, suggesting a broader therapeutic mechanism than previously appreciated.
  • Myelin-Specific vs. General Immune Response: The phenotypic differences (memory and CD20 expression) were specific to myelin-reactive CD8+ T cells, not influenza-reactive ones. This highlights the specificity of the observed immune dysregulation in MS.

Key Results

  • No Difference in Frequency: There were no significant differences in the ex vivo frequencies of myelin-specific CD8+ T cells between untreated MS patients and healthy controls.
  • Increased Activation in MS: A higher proportion of myelin-specific CD8+ T cells in MS patients exhibited a memory phenotype and expressed CD20 compared to controls.
  • Influenza Specificity: These phenotypic differences were not observed in influenza-specific CD8+ T cells, suggesting a specific abnormality related to self-antigens in MS.
  • Therapeutic Depletion: Following anti-CD20 mAb treatment, the proportion of memory and CD20+ CD8+ T cells specific for certain myelin epitopes was significantly reduced. This reduction was more pronounced for myelin-specific T cells than for influenza-specific ones.

Limitations and Future Work

  • Limited Epitope Set: The study focused on a specific set of 5 myelin CD8+ T cell epitopes. The authors acknowledge that other myelin CD8+ T cell epitopes may exist and could exhibit different characteristics.
  • Mechanism of CD20 Expression on T Cells: The precise molecular mechanisms by which T cells express CD20 are not fully understood, and the differential response of myelin- vs. influenza-specific CD20+ T cells to anti-CD20 therapy warrants further investigation.
  • Regulatory/Suppressive Roles: While the study points to a pathogenic role for activated myelin-specific CD8+ T cells, the authors acknowledge that CD8+ T cells can also have regulatory or suppressive functions, which were not explored here.
  • Future Directions: The findings strongly suggest that targeting these activated myelin-specific CD8+ T cells could be a promising therapeutic strategy for MS. Further research could explore specific ways to selectively target these cells or understand the triggers for their activation.

Summary updated

Abstract

CD8<sup>+</sup> T cells are believed to play an important role in multiple sclerosis (MS), yet their role in MS pathogenesis remains poorly defined. Although myelin proteins are considered potential autoantigenic targets, prior studies of myelin-reactive CD8<sup>+</sup> T cells in MS have relied on in vitro stimulation, thereby limiting accurate measurement of their ex vivo precursor frequencies and phenotypes. Peptide:MHC I tetramers were used to identify and validate 5 myelin CD8<sup>+</sup> T cell epitopes, including 2 newly described determinants in humans. The validated tetramers were used to measure the ex vivo precursor frequencies and phenotypes of myelin-specific CD8<sup>+</sup> T cells in the peripheral blood of untreated MS patients and HLA allele-matched healthy controls. In parallel, CD8<sup>+</sup> T cell responses against immunodominant influenza epitopes were also measured. There were no differences in ex vivo frequencies of tetramer-positive myelin-specific CD8<sup>+</sup> T cells between MS patients and control subjects. An increased proportion of myelin-specific CD8<sup>+</sup> T cells in MS patients exhibited a memory phenotype and expressed CD20 compared to control subjects, while there were no phenotypic differences observed among influenza-specific CD8<sup>+</sup> T cells. Longitudinal assessments were also measured in a subset of MS patients subsequently treated with anti-CD20 monoclonal antibody therapy. The proportion of memory and CD20<sup>+</sup> CD8<sup>+</sup> T cells specific for certain myelin but not influenza epitopes was significantly reduced following anti-CD20 treatment. This study, representing a characterization of unmanipulated myelin-reactive CD8<sup>+</sup> T cells in MS, indicates these cells may be attractive targets in MS therapy.
BibTeX
@inproceedings{sabatino2019anti,
  author = {Joseph J. Sabatino and Michael R. Wilson and Peter A. Calabresi and Stephen L. Hauser and Jonathan P. Schneck and Scott S. Zamvil},
  title = {{Anti-CD20 therapy depletes activated myelin-specific CD8<sup>+</sup>T cells in multiple sclerosis}},
  booktitle = {Proceedings of the National Academy of Sciences},
  year = {2019},
  doi = {10.1073/pnas.1915309116},
}
Figure